Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jul;85(3):697–703. doi: 10.1111/j.1476-5381.1985.tb10566.x

Solubilization and characterization of high and low affinity pirenzepine binding sites from rat cerebral cortex.

C P Berrie, N J Birdsall, E C Hulme, M Keen, J M Stockton
PMCID: PMC1916521  PMID: 4027484

Abstract

An apparently monomeric form of the digitonin-solubilized muscarinic acetylcholine receptor from the rat cerebral cortex retains a high affinity of 7 X 10(7) M-1 for pirenzepine. Muscarinic receptor binding sites in the rat cerebral cortex with a low affinity for pirenzepine are solubilized with relatively little change in affinity. The ability of pirenzepine to distinguish between subtypes of muscarinic binding site in the cerebral cortex is manifest in both the membrane-bound and soluble state.

Full text

PDF
697

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berrie C. P., Birdsall N. J., Haga K., Haga T., Hulme E. C. Hydrodynamic properties of muscarinic acetylcholine receptors solubilized from rat forebrain. Br J Pharmacol. 1984 Aug;82(4):839–851. doi: 10.1111/j.1476-5381.1984.tb16481.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berrie C. P., Birdsall N. J., Hulme E. C., Keen M., Stockton J. M. Solubilization and characterization of guanine nucleotide-sensitive muscarinic agonist binding sites from rat myocardium. Br J Pharmacol. 1984 Aug;82(4):853–861. doi: 10.1111/j.1476-5381.1984.tb16482.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Birdsall N. J., Burgen A. S., Hulme E. C. The binding of agonists to brain muscarinic receptors. Mol Pharmacol. 1978 Sep;14(5):723–736. [PubMed] [Google Scholar]
  4. Birdsall N. J., Hulme E. C., Stockton J., Burgen A. S., Berrie C. P., Hammer R., Wong E. H., Zigmond M. J. Muscarinic receptor subclasses: evidence from binding studies. Adv Biochem Psychopharmacol. 1983;37:323–329. [PubMed] [Google Scholar]
  5. Brown D. A., Forward A., Marsh S. Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol. 1980;71(2):362–364. doi: 10.1111/j.1476-5381.1980.tb10948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Caulfield M. P., Higgins G. A., Straughan D. W. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. J Pharm Pharmacol. 1983 Feb;35(2):131–132. doi: 10.1111/j.2042-7158.1983.tb04290.x. [DOI] [PubMed] [Google Scholar]
  7. Hammer R., Berrie C. P., Birdsall N. J., Burgen A. S., Hulme E. C. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature. 1980 Jan 3;283(5742):90–92. doi: 10.1038/283090a0. [DOI] [PubMed] [Google Scholar]
  8. Hammer R., Giachetti A. Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 1982 Dec 27;31(26):2991–2998. doi: 10.1016/0024-3205(82)90066-2. [DOI] [PubMed] [Google Scholar]
  9. Hammer R. Subclasses of muscarinic receptors and pirenzepine. Further experimental evidence. Scand J Gastroenterol Suppl. 1982;72:59–67. [PubMed] [Google Scholar]
  10. Hulme E. C., Berrie C. P., Birdsall N. J., Burgen A. S. Two populations of binding sites for muscarinic antagonists in the rat heart. Eur J Pharmacol. 1981 Jul 17;73(2-3):137–142. doi: 10.1016/0014-2999(81)90085-6. [DOI] [PubMed] [Google Scholar]
  11. Hulme E. C., Berrie C. P., Birdsall N. J., Jameson M., Stockton J. M. Regulation of muscarinic agonist binding by cations and guanine nucleotides. Eur J Pharmacol. 1983 Oct 14;94(1-2):59–72. doi: 10.1016/0014-2999(83)90442-9. [DOI] [PubMed] [Google Scholar]
  12. Hulme E. C., Birdsall N. J., Burgen A. S., Mehta P. The binding of antagonists to brain muscarinic receptors. Mol Pharmacol. 1978 Sep;14(5):737–750. [PubMed] [Google Scholar]
  13. Luthin G. R., Wolfe B. B. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain. J Pharmacol Exp Ther. 1984 Mar;228(3):648–655. [PubMed] [Google Scholar]
  14. Roeske W. R., Venter J. C. The differential loss of [3H]pirenzepine vs [3H] (-) quinuclidinylbenzilate binding to soluble rat brain muscarinic receptors indicates that pirenzepine binds to an allosteric state of the muscarinic receptor. Biochem Biophys Res Commun. 1984 Feb 14;118(3):950–957. doi: 10.1016/0006-291x(84)91487-6. [DOI] [PubMed] [Google Scholar]
  15. Watson M., Roeske W. R., Johnson P. C., Yamamura H. I. [3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia. Brain Res. 1984 Jan 2;290(1):179–182. doi: 10.1016/0006-8993(84)90751-0. [DOI] [PubMed] [Google Scholar]
  16. Watson M., Roeske W. R., Yamamura H. I. [3h]pirenzepine selectively identifies a high affinity population of muscarinic cholinergic receptors in the rat cerebral cortex. Life Sci. 1982 Nov 1;31(18):2019–2023. doi: 10.1016/0024-3205(82)90041-8. [DOI] [PubMed] [Google Scholar]
  17. Watson M., Yamamura H. I., Roeske W. R. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci. 1983 Jun 27;32(26):3001–3011. doi: 10.1016/0024-3205(83)90652-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES